Amgen Inc. (LON:0R0T)

London flag London · Delayed Price · Currency is GBP · Price in USD
295.09
-1.55 (-0.52%)
At close: Aug 1, 2025
-0.52%
Market Cap119.99B
Revenue (ttm)26.41B
Net Income (ttm)4.59B
Shares Outn/a
EPS (ttm)8.47
PE Ratio26.13
Forward PE14.27
Dividend7.21 (2.44%)
Ex-Dividend DateMay 16, 2025
Volume455
Average Volume528
Open294.77
Previous Close296.64
Day's Range292.67 - 297.88
52-Week Range253.20 - 340.97
Betan/a
RSI50.34
Earnings DateAug 4, 2025

About DISH Network

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company’s principal products include Enbrel for the treatment of rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet’s disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascul... [Read more]

Industry Biological Products, Except Diagnostic Substances
Founded 1980
Employees 28,000
Stock Exchange London Stock Exchange
Ticker Symbol 0R0T
Full Company Profile

Financial Performance

In 2024, Amgen's revenue was $33.42 billion, an increase of 18.57% compared to the previous year's $28.19 billion. Earnings were $4.09 billion, a decrease of -39.11%.

Financial numbers in GBP Financial Statements

News

There is no news available yet.